SCHEMBL5865566

SCHEMBL5865566

CS(=O)(=O)c1cc(C(=C(Cl)Cl)c2ccc(Br)cc2)ccc1Br

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 1/20 0.38
TP53 P04637 1/20 0.38
AKR1C3 P42330 1/20 0.37
ALDH1A1 P00352 2/20 0.36
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
MAPK1 P28482 2/20 0.36
CCR2 P41597 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP3A4 P08684 1/20 0.35
TSHR P16473 1/20 0.35
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5865494 0.90 TSHR (0.50) HTTAKR1C3ALDH1A1MAPK1CCR2
SCHEMBL5865698 0.88 CCR2 (0.39) AKR1C3ALDH1A1CES2CES1MAPK1
SCHEMBL5865564 0.87 MAPT (0.43) MAPTLMNAAKR1C3ALDH1A1MAPK1
SCHEMBL5865619 0.84 CCR2 (0.41) MAPTLMNAAKR1C3ALDH1A1CES2
SCHEMBL5865539 0.78 MAPK1 (0.50) MAPTAKR1C3ALDH1A1MAPK1CCR2
SCHEMBL8246019 0.77 HTT (0.59) LMNAHTTALDH1A1MAPK1SMN1; SMN2
SCHEMBL27289109 0.76 HTT (0.43) HTTMAPK1SMN1; SMN2
SCHEMBL4157506 0.74 LMNA (0.47) LMNAALDH1A1CCR2SMN1; SMN2MEN1
SCHEMBL9494805 0.74 TSHR (0.59) MAPTLMNACES2CES1MAPK1
SCHEMBL5865511 0.74 L3MBTL1 (0.53) ALDH1A1MAPK1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7091248-B2 Treatment of adrenocortical hypersecretion and tumor growth BRANDT INGVAR 2006-08-15 US disclosed
US-20040242705-A1 Novel treatment of adrenocortical hypersecretion and tumour growth BRANDT INGVAR (SE) 2004-12-02 US disclosed
EP-1412311-A1 NOVEL TREATMENT OF ADRENOCORTICAL HYPERSECRETION AND TUMOUR GROWTH Brandt, Ingvar (SE) 2004-04-28 EP disclosed
WO-2003002495-A1 NOVEL TREATMENT OF ADRENOCORTICAL HYPERSECRETION AND TUMOUR GROWTH BRANDT INGVAR (SE) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242705-A1 Novel treatment of adrenocortical hypersecretion and tumour growth NR3C2, NR5A1, NR3C1 MAPT 4158/4885LMNA 4842/4885HTT 4568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.